NEW

Ultrapotent compound may help treat C. diff, reduce recurrence

Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S. Only two antibiotics, vancomycin and fidaxomicin, are FDA-approved for the treatment of C. diff, but even these therapies suffer from high treatment failure and...

Tampa General Hospital, Philips announce partnership

The seven-year agreement will upgrade technology throughout the hospital and improve efficiency Tampa General Hospital (TGH) and Royal Philips announced they are creating a long-term strategic partnership designed to keep Tampa General Hospital at the forefront of...

PENTAX Medical Launches Bronchoscopes, Video Processor in U.S.

PENTAX Medical has launched the EB-J10 Series Bronchoscopes in the U.S., with FDA 510(k) clearance, along with a new DEFINA Video Processor. As the newest HD solution in pulmonology, the EB-J10 Series Bronchoscopes offer crisp, HD visualization of the bronchus, along...

Nautilus Medical Launches All-in-One DICOM Surgical Recorder

Nautilus Medical Technologies has announced an advanced all-in-one surgery recorder, named TeleRay Record, for use with any endoscope, headset, c-arm, vascular, ultrasound, c-arms and more. Users will be able to store up to 150 hours of HD medical videos form a...

Clinical Study Shows Efficacy of Dual-Ring Wound Protector in Lowering Surgical Site Infection in Pancreaticoduodenectomy Procedures

New clinical evidence demonstrates the value of Applied Medical’s Alexis wound protector/retractor in pancreaticoduodenectomy (PD) procedures, also known as Whipple procedures.

study published this month in the Annals of Surgery showcases a significant reduction in PD surgical site infection (SSI) when the dual-ring Alexis wound protector/retractor was used. The Alexis wound protector/retractor lowered incisional SSI in PD procedures by 52 percent compared to cases that did not utilize a wound protector.

The volume of PD cases has been increasing over the past two decades,1 yet postoperative morbidity remains high, up to 40 percent in high-volume pancreatic centers,2 with a substantial amount resulting from SSI. The risk of incisional SSI is even higher in cases requiring biliary drainage prior to the procedure.1

In addition to reducing incisional SSI in PD procedures, the Alexis wound protector/retractor has been clinically proven to reduce incisional SSI across multiple surgical specialties.

“It’s our company’s mission to make a meaningful, positive difference by enhancing surgical outcomes,” said Serene Wachli, president of the Horizon II Division at Applied Medical. “We’re proud to design, develop and manufacture our Alexis wound protectors, which have been shown to be effective in helping reduce SSI in a wide variety of procedures.”

Study Design

The study was a multicenter, parallel, dual-arm, double-blind, randomized controlled trial that evaluated the efficacy of the Alexis wound protector/retractor to reduce the risk of incisional SSI among patients with a biliary stent undergoing an elective PD. The study compared the use of the dual-ring wound protector to the current standard of care at the Foothills Medical Centre and The Ottawa Hospital in Calgary and Ottawa, Canada, respectively. The Alexis wound protector/retractor group was comprised of 57 patients and the no-wound-protector group was comprised of 50 patients. After observing that the risk of incisional SSI was significantly lower with the use of dual-ring wound protectors, the data safety panel stopped the trial at the first planned interim analysis due to the dramatically positive treatment effect and the understanding of the economic impact associated with addressing incisional SSI occurrence.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X